Cellectis Stock Surges Nearly 9% Following Key FDA Approval
The French biotech company experienced a significant rebound session following the announcement of a major U.S. regulatory designation for its allogeneic CAR-T candidate. The stock is recovering after several weeks of decline, attempting to reclaim its technical benchmarks.
RMAT Status from the FDA Boosts Interest in Lasmé-cel
Cellectis stock rose by 8.68% to €2.73 at the close, following the announcement of the RMAT designation granted by the FDA to lasmé-cel, its allogeneic CAR-T candidate targeting the CD22 antigen. The advanced regenerative medicine therapy status facilitates accelerated interactions with the U.S. regulator for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. This regulatory progress comes as the biotech had confirmed a secure cash position until 2027 during the Q1 2026 report (May 11, 2026), with a stable net loss of $17.8 million.
A Technical Rebound That Still Leaves the Stock Below Its Three Moving Averages
Despite the surge, the price remains below the MM20 (€3.08), MM50 (€3.20), and MM200 (€3.22), with a gap of more than 15% from the latter. The RSI at 28 was emerging from a marked oversold zone, highlighting the magnitude of the day's rebound. The stock has rebounded from the support threshold at €2.51, tested at the beginning of the week, and still shows a decline of nearly 17% over three months. However, its performance over the past year remains positive at nearly 110%. The movement goes against the trend of the CAC 40, which fell by 0.51% at the close, in a context of increased volatility (VIX up by 14.4%). The resistance at €3.58 represents the next technical benchmark for the stock, and the MM20 at €3.08 is the intermediate level to surpass to confirm the rebound.
